Contineum Therapeutics (NASDAQ:CTNM) Issues Quarterly Earnings Results

Contineum Therapeutics (NASDAQ:CTNM) released its earnings results on Wednesday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01, Zacks reports.

Contineum Therapeutics Stock Performance

NASDAQ:CTNM traded down $0.15 during mid-day trading on Friday, hitting $18.40. The company’s stock had a trading volume of 44,394 shares, compared to its average volume of 73,289. The stock has a fifty day moving average of $17.58 and a 200-day moving average of $17.77. Contineum Therapeutics has a fifty-two week low of $13.27 and a fifty-two week high of $22.00.

Analysts Set New Price Targets

CTNM has been the subject of several research analyst reports. Robert W. Baird assumed coverage on Contineum Therapeutics in a research note on Tuesday, October 22nd. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Royal Bank of Canada cut their price objective on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating on the stock in a research note on Thursday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $29.25.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).